Caribou Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive (Loss) Income · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| BALANCE—December 31, 2023 | 88,448,948 | $8 | $667,648 | $30 | $(299,285) | $368,401 |
| Issuance of common stock under ESPP | 122,035 | — | 667 | — | — | 667 |
| Issuance of common stock on exercise of options | 134,347 | — | 489 | — | — | 489 |
| Issuance of common stock in connection with our ATM offering, net of offering expenses | 1,594,171 | 1 | 11,329 | — | — | 11,330 |
| Issuance of common stock upon vesting of RSUs | 15,000 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 3,988 | — | — | 3,988 |
| Net loss | — | — | — | — | (41,234) | (41,234) |
| Other comprehensive loss | — | — | — | (352) | — | (352) |
| BALANCE—March 31, 2024 | 90,314,501 | $9 | $684,121 | $(322) | $(340,519) | $343,289 |
| Issuance of common stock under ESPP | 400 | — | 2 | — | — | $2 |
| Issuance of common stock on exercise of options | 47,870 | — | 129 | — | — | $129 |
| Stock-based compensation expense | — | — | 4,738 | — | — | 4,738 |
| Net loss | — | — | — | — | (37,697) | (37,697) |
| Other comprehensive income | — | — | — | 3 | — | 3 |
| BALANCE—June 30, 2024 | 90,362,771 | $9 | $688,990 | $(319) | $(378,216) | $310,464 |
| BALANCE—December 31, 2022 | 61,029,184 | $6 | $499,598 | $(1,518) | $(197,215) | $300,871 |
| Issuance of common stock under ESPP | 70,271 | — | 404 | — | — | 404 |
| Issuance of common stock on exercise of options | 55,433 | — | 115 | — | — | 115 |
| Issuance of common stock in connection with our ATM offering, net of offering expenses | 168,635 | — | 1,007 | — | — | 1,007 |
| Stock-based compensation expense | — | — | 3,131 | — | — | 3,131 |
| Net loss | — | — | — | — | (28,044) | (28,044) |
| Other comprehensive income | — | — | — | 788 | — | 788 |
| BALANCE—March 31, 2023 | 61,323,523 | $6 | $504,255 | $(730) | $(225,259) | $278,272 |
| Issuance of common stock on exercise of options | 86,085 | — | 236 | — | — | 236 |
| Issuance of common stock pursuant to private placement with Pfizer | 4,690,431 | — | 17,290 | — | — | 17,290 |
| Stock-based compensation expense | — | — | 3,585 | — | — | 3,585 |
| Net loss | — | — | — | — | (29,519) | (29,519) |
| Other comprehensive loss | — | — | — | (406) | — | (406) |
| BALANCE—June 30, 2023 | 66,100,039 | $6 | $525,366 | $(1,136) | $(254,778) | $269,458 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.